Humanigen Announces Participation and Presentation at Multiple Conferences in October

BURLINGAME, Calif.–(Business enterprise WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-phase biopharmaceutical organization concentrated on stopping and dealing with an immune hyper-response identified as ‘cytokine storm,’ announced that administration will present and participate at numerous digital trader conferences in October 2021. Facts of the conferences are as follows:

Guggenheim 2nd Annual Vaccines and Infectious Ailments Convention

Dale Chappell, MD, Chief Scientific Officer, will participate in a hearth chat at 9:00am EDT on Oct 5, 2021. A livestream will be offered and a webcast url to a recording of the occasion will be posted to the “Events and Presentations” section of Humanigen’s investor relations website just after the event.

Webcast: https://kvgo.com/guggenheim/humanigen-inc-oct-2021

The webcast will be archived for up to just one 12 months less than the Trader Relations part of the company’s website at www.ir.humanigen.com

Sachs Associates 8th Yearly HealthTech Expense Discussion board

Cameron Durrant, Chairman & CEO participated in a panel to explore “Advances in Covid Therapeutics”, which was pre-recorded and will be offered to members in the forum starting at 5:20am EDT on Oct 6, 2021. Sachs and Associates plans to share a video of the panel via its social media networks 1-2 months just after the event. For extra facts, you should access the event agenda at https://sachsevent.com/party/8th-htif/agenda.

LD Micro Principal Event XIV (Digital and In-human being)

Humanigen will take part in this blend virtual and in-man or woman occasion on Oct 12, 2021. Cameron Durrant, Chairman & CEO will supply a company update, which was pre-recorded and will become available at 11:30am EDT on October 12. A corresponding presentation will also be created at the same time in-particular person at the conference. Registration is necessary to watch the webcast.

Webcast: https://me21.mysequire.com/

Cytokines 2021 – 9^th Once-a-year Meeting of the Global Cytokine & Interferon Society

The Intercontinental Cytokine & Interferon Society (ICIS), is the world’s greatest multidisciplinary organization advancing each essential and medical analysis unique to the position of cytokines in well being and disease. Humanigen will existing details from its Live-AIR Stage 3 study for the duration of the Exhibitor Breaking Information Session virtual meeting platform, which will consider spot from 1:15-2:45pm Central European Time (CET) on October 17, 2021. Humanigen will also have a digital healthcare information and facts booth at the assembly and is sponsoring a session, entitled “Targeting Cytokines in COVID-19”, as a result of an unrestricted educational grant. The session will be moderated by Cameron Durrant, Chairmen and CEO of Humanigen, alongside with Christopher Hunter, the Mindy Halikman Heyer Distinguished Professor of Pathobiology at the Faculty of Veterinary Medicine of the University of Pennsylvania who will turn out to be President ICIS adhering to the October Cytokines 2021 meeting. The session is scheduled to consider position from 11:45am-12:45pm CET on Oct 19th. For far more facts please evaluate the Cytokine 2021 web-site: https://cardiff.cytokinesociety.org/

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a medical-stage biopharmaceutical business centered on protecting against and treating an immune hyper-reaction called ‘cytokine storm’. Lenzilumab is a first-in course antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating variable (GM-CSF). Success from preclinical designs point out GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines concerned in the cytokine storm. Early in the COVID-19 pandemic, investigation confirmed significant amounts of GM-CSF secreting T cells ended up affiliated with disease severity and intensive treatment device admission. Humanigen’s Phase 3 Are living-AIR study indicates early intervention with lenzilumab may stop effects of a comprehensive-blown cytokine storm in hospitalized sufferers with COVID-19. Humanigen is building lenzilumab as a procedure for cytokine storm linked with COVID-19 and CD19-specific Automobile-T cell therapies and is also exploring the performance of lenzilumab in other inflammatory conditions such as acute Graft compared to Host Sickness in individuals going through allogeneic hematopoietic stem mobile transplantation, eosinophilic asthma, and rheumatoid arthritis. For much more information, visit www.humanigen.com and abide by Humanigen on LinkedIn, Twitter, and Fb.

Ahead-On the lookout Statements

All statements other than statements of historical info contained in this push release are forward-on the lookout statements. Forward-hunting statements mirror management’s existing awareness, assumptions, judgment, and anticipations relating to future overall performance or activities. Though administration believes that the expectations mirrored in these statements are fair, they give no assurance that this kind of anticipations will establish to be appropriate, and you must be aware that genuine activities or results may possibly differ materially from these contained in the forward- seeking statements. Words these as “will,” “assume,” “intend,” “strategy,” “probable,” “attainable,” “aims,” “accelerate,” “proceed,” and related expressions identify forward-wanting statements, together with, without limitation, statements about our designs relating to lenzilumab.

Ahead-wanting statements are matter to a variety of challenges and uncertainties which includes, but not limited to, the dangers inherent in our absence of profitability and require for extra cash to develop our enterprise our dependence on partners to even further the enhancement of our products candidates the uncertainties inherent in the progress, attainment of the requisite regulatory authorizations and approvals and start of any new pharmaceutical merchandise the final result of pending or upcoming litigation and the many challenges and uncertainties described in the “Risk Elements” sections of our most up-to-date annual and quarterly studies and other filings with the SEC.

All ahead-looking statements are expressly capable in their entirety by this cautionary detect. You must not count on any forward-on the lookout statements as predictions of potential functions. We undertake no obligation to revise or update any ahead-wanting statements built in this presentation to mirror occasions or instances just after the day hereof, to mirror new facts or the occurrence of unanticipated functions, to update the motives why true effects could differ materially from these expected in the ahead-wanting statements, in every situation, apart from as expected by legislation.